Table of Content

1 Neuromuscular Blocking Agent (NMBA) Market Overview
1.1 Product Overview and Scope of Neuromuscular Blocking Agent (NMBA)
1.2 Neuromuscular Blocking Agent (NMBA) Segment by Type
1.2.1 Global Neuromuscular Blocking Agent (NMBA) Market Value Comparison by Type (2024-2034)
1.2.2 Depolarizing
1.2.3 Non-depolarizing
1.3 Neuromuscular Blocking Agent (NMBA) Segment by Application
1.3.1 Global Neuromuscular Blocking Agent (NMBA) Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Pharmacy
1.3.5 Others
1.4 Global Neuromuscular Blocking Agent (NMBA) Market Size Estimates and Forecasts
1.4.1 Global Neuromuscular Blocking Agent (NMBA) Revenue 2018-2034
1.4.2 Global Neuromuscular Blocking Agent (NMBA) Sales 2018-2034
1.4.3 Global Neuromuscular Blocking Agent (NMBA) Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Neuromuscular Blocking Agent (NMBA) Market Competition by Manufacturers
2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturers (2018-2023)
2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Neuromuscular Blocking Agent (NMBA) Average Price by Manufacturers (2018-2023)
2.4 Global Neuromuscular Blocking Agent (NMBA) Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Neuromuscular Blocking Agent (NMBA), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neuromuscular Blocking Agent (NMBA), Product Type & Application
2.7 Neuromuscular Blocking Agent (NMBA) Market Competitive Situation and Trends
2.7.1 Neuromuscular Blocking Agent (NMBA) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neuromuscular Blocking Agent (NMBA) Players Market Share by Revenue
2.7.3 Global Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario by Region
3.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Neuromuscular Blocking Agent (NMBA) Global Neuromuscular Blocking Agent (NMBA) Sales by Region: 2018-2034
3.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Region: 2018-2023
3.2.2 Global Neuromuscular Blocking Agent (NMBA) Sales by Region: 2024-2034
3.3 Global Neuromuscular Blocking Agent (NMBA) Global Neuromuscular Blocking Agent (NMBA) Revenue by Region: 2018-2034
3.3.1 Global Neuromuscular Blocking Agent (NMBA) Revenue by Region: 2018-2023
3.3.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Region: 2024-2034
3.4 North America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.4.1 North America Neuromuscular Blocking Agent (NMBA) Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2018-2034)
3.4.3 North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.5.1 Europe Neuromuscular Blocking Agent (NMBA) Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2018-2034)
3.5.3 Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.6.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Country (2018-2034)
3.6.3 Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.7.1 Latin America Neuromuscular Blocking Agent (NMBA) Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country (2018-2034)
3.7.3 Latin America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Country
3.8.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2018-2034)
3.8.3 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2018-2034)
4.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2018-2023)
4.1.2 Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2024-2034)
4.1.3 Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2018-2034)
4.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2018-2034)
4.2.1 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2018-2023)
4.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2024-2034)
4.2.3 Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type (2018-2034)
4.3 Global Neuromuscular Blocking Agent (NMBA) Price by Type (2018-2034)
5 Segment by Application
5.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2018-2034)
5.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2018-2023)
5.1.2 Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2024-2034)
5.1.3 Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2018-2034)
5.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2018-2034)
5.2.1 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2018-2023)
5.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2024-2034)
5.2.3 Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application (2018-2034)
5.3 Global Neuromuscular Blocking Agent (NMBA) Price by Application (2018-2034)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Hengrui Pharmaceutical
6.4.1 Hengrui Pharmaceutical Corporation Information
6.4.2 Hengrui Pharmaceutical Description and Business Overview
6.4.3 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.4.5 Hengrui Pharmaceutical Recent Developments/Updates
6.5 Abbott Laboratories
6.5.1 Abbott Laboratories Corporation Information
6.5.2 Abbott Laboratories Description and Business Overview
6.5.3 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.5.5 Abbott Laboratories Recent Developments/Updates
6.6 Fresenius Kabi
6.6.1 Fresenius Kabi Corporation Information
6.6.2 Fresenius Kabi Description and Business Overview
6.6.3 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.6.5 Fresenius Kabi Recent Developments/Updates
6.7 Sandoz
6.6.1 Sandoz Corporation Information
6.6.2 Sandoz Description and Business Overview
6.6.3 Sandoz Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sandoz Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.7.5 Sandoz Recent Developments/Updates
6.8 Somerset Therapeutics
6.8.1 Somerset Therapeutics Corporation Information
6.8.2 Somerset Therapeutics Description and Business Overview
6.8.3 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.8.5 Somerset Therapeutics Recent Developments/Updates
6.9 Guike Pharmaceutical
6.9.1 Guike Pharmaceutical Corporation Information
6.9.2 Guike Pharmaceutical Description and Business Overview
6.9.3 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.9.5 Guike Pharmaceutical Recent Developments/Updates
6.10 Shanghai Pharmaceuticals
6.10.1 Shanghai Pharmaceuticals Corporation Information
6.10.2 Shanghai Pharmaceuticals Description and Business Overview
6.10.3 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.10.5 Shanghai Pharmaceuticals Recent Developments/Updates
6.11 Themis Medicare
6.11.1 Themis Medicare Corporation Information
6.11.2 Themis Medicare Neuromuscular Blocking Agent (NMBA) Description and Business Overview
6.11.3 Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Themis Medicare Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.11.5 Themis Medicare Recent Developments/Updates
6.12 Nanjing King-Friend
6.12.1 Nanjing King-Friend Corporation Information
6.12.2 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Description and Business Overview
6.12.3 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product Portfolio
6.12.5 Nanjing King-Friend Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neuromuscular Blocking Agent (NMBA) Industry Chain Analysis
7.2 Neuromuscular Blocking Agent (NMBA) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neuromuscular Blocking Agent (NMBA) Production Mode & Process
7.4 Neuromuscular Blocking Agent (NMBA) Sales and Marketing
7.4.1 Neuromuscular Blocking Agent (NMBA) Sales Channels
7.4.2 Neuromuscular Blocking Agent (NMBA) Distributors
7.5 Neuromuscular Blocking Agent (NMBA) Customers
8 Neuromuscular Blocking Agent (NMBA) Market Dynamics
8.1 Neuromuscular Blocking Agent (NMBA) Industry Trends
8.2 Neuromuscular Blocking Agent (NMBA) Market Drivers
8.3 Neuromuscular Blocking Agent (NMBA) Market Challenges
8.4 Neuromuscular Blocking Agent (NMBA) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Neuromuscular Blocking Agent (NMBA) Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Neuromuscular Blocking Agent (NMBA) Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Neuromuscular Blocking Agent (NMBA) Market Competitive Situation by Manufacturers in 2024
Table 4. Global Neuromuscular Blocking Agent (NMBA) Sales (MT) of Key Manufacturers (2018-2023)
Table 5. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Neuromuscular Blocking Agent (NMBA) Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Neuromuscular Blocking Agent (NMBA) Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Neuromuscular Blocking Agent (NMBA) Average Price (USD/MT) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Neuromuscular Blocking Agent (NMBA), Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Neuromuscular Blocking Agent (NMBA), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Neuromuscular Blocking Agent (NMBA), Product Type & Application
Table 12. Global Key Manufacturers of Neuromuscular Blocking Agent (NMBA), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Neuromuscular Blocking Agent (NMBA) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromuscular Blocking Agent (NMBA) as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Neuromuscular Blocking Agent (NMBA) Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Neuromuscular Blocking Agent (NMBA) Sales by Region (2018-2023) & (MT)
Table 18. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2018-2023)
Table 19. Global Neuromuscular Blocking Agent (NMBA) Sales by Region (2024-2034) & (MT)
Table 20. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2024-2034)
Table 21. Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2018-2023)
Table 23. Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2024-2034)
Table 25. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2018-2023) & (MT)
Table 27. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2024-2034) & (MT)
Table 28. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2018-2023) & (MT)
Table 32. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2024-2034) & (MT)
Table 33. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2018-2023) & (MT)
Table 37. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2024-2034) & (MT)
Table 38. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Neuromuscular Blocking Agent (NMBA) Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country (2018-2023) & (MT)
Table 42. Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country (2024-2034) & (MT)
Table 43. Latin America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2018-2023) & (MT)
Table 47. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2024-2034) & (MT)
Table 48. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Neuromuscular Blocking Agent (NMBA) Sales (MT) by Type (2018-2023)
Table 51. Global Neuromuscular Blocking Agent (NMBA) Sales (MT) by Type (2024-2034)
Table 52. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2018-2023)
Table 53. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2024-2034)
Table 54. Global Neuromuscular Blocking Agent (NMBA) Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Neuromuscular Blocking Agent (NMBA) Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type (2018-2023)
Table 57. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type (2024-2034)
Table 58. Global Neuromuscular Blocking Agent (NMBA) Price (USD/MT) by Type (2018-2023)
Table 59. Global Neuromuscular Blocking Agent (NMBA) Price (USD/MT) by Type (2024-2034)
Table 60. Global Neuromuscular Blocking Agent (NMBA) Sales (MT) by Application (2018-2023)
Table 61. Global Neuromuscular Blocking Agent (NMBA) Sales (MT) by Application (2024-2034)
Table 62. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2018-2023)
Table 63. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2024-2034)
Table 64. Global Neuromuscular Blocking Agent (NMBA) Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Neuromuscular Blocking Agent (NMBA) Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application (2018-2023)
Table 67. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application (2024-2034)
Table 68. Global Neuromuscular Blocking Agent (NMBA) Price (USD/MT) by Application (2018-2023)
Table 69. Global Neuromuscular Blocking Agent (NMBA) Price (USD/MT) by Application (2024-2034)
Table 70. AbbVie Corporation Information
Table 71. AbbVie Description and Business Overview
Table 72. AbbVie Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 73. AbbVie Neuromuscular Blocking Agent (NMBA) Product
Table 74. AbbVie Recent Developments/Updates
Table 75. GlaxoSmithKline Corporation Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 78. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product
Table 79. GlaxoSmithKline Recent Developments/Updates
Table 80. Pfizer Corporation Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 83. Pfizer Neuromuscular Blocking Agent (NMBA) Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Hengrui Pharmaceutical Corporation Information
Table 86. Hengrui Pharmaceutical Description and Business Overview
Table 87. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 88. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product
Table 89. Hengrui Pharmaceutical Recent Developments/Updates
Table 90. Abbott Laboratories Corporation Information
Table 91. Abbott Laboratories Description and Business Overview
Table 92. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 93. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product
Table 94. Abbott Laboratories Recent Developments/Updates
Table 95. Fresenius Kabi Corporation Information
Table 96. Fresenius Kabi Description and Business Overview
Table 97. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 98. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product
Table 99. Fresenius Kabi Recent Developments/Updates
Table 100. Sandoz Corporation Information
Table 101. Sandoz Description and Business Overview
Table 102. Sandoz Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 103. Sandoz Neuromuscular Blocking Agent (NMBA) Product
Table 104. Sandoz Recent Developments/Updates
Table 105. Somerset Therapeutics Corporation Information
Table 106. Somerset Therapeutics Description and Business Overview
Table 107. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 108. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product
Table 109. Somerset Therapeutics Recent Developments/Updates
Table 110. Guike Pharmaceutical Corporation Information
Table 111. Guike Pharmaceutical Description and Business Overview
Table 112. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 113. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product
Table 114. Guike Pharmaceutical Recent Developments/Updates
Table 115. Shanghai Pharmaceuticals Corporation Information
Table 116. Shanghai Pharmaceuticals Description and Business Overview
Table 117. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 118. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product
Table 119. Shanghai Pharmaceuticals Recent Developments/Updates
Table 120. Themis Medicare Corporation Information
Table 121. Themis Medicare Description and Business Overview
Table 122. Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 123. Themis Medicare Neuromuscular Blocking Agent (NMBA) Product
Table 124. Themis Medicare Recent Developments/Updates
Table 125. Nanjing King-Friend Corporation Information
Table 126. Nanjing King-Friend Description and Business Overview
Table 127. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 128. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product
Table 129. Nanjing King-Friend Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Neuromuscular Blocking Agent (NMBA) Distributors List
Table 133. Neuromuscular Blocking Agent (NMBA) Customers List
Table 134. Neuromuscular Blocking Agent (NMBA) Market Trends
Table 135. Neuromuscular Blocking Agent (NMBA) Market Drivers
Table 136. Neuromuscular Blocking Agent (NMBA) Market Challenges
Table 137. Neuromuscular Blocking Agent (NMBA) Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Neuromuscular Blocking Agent (NMBA)
Figure 2. Global Neuromuscular Blocking Agent (NMBA) Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2024 & 2034
Figure 4. Depolarizing Product Picture
Figure 5. Non-depolarizing Product Picture
Figure 6. Global Neuromuscular Blocking Agent (NMBA) Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2024 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Pharmacy
Figure 11. Others
Figure 12. Global Neuromuscular Blocking Agent (NMBA) Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Neuromuscular Blocking Agent (NMBA) Market Size (2018-2034) & (US$ Million)
Figure 14. Global Neuromuscular Blocking Agent (NMBA) Sales (2018-2034) & (MT)
Figure 15. Global Neuromuscular Blocking Agent (NMBA) Average Price (USD/MT) & (2018-2034)
Figure 16. Neuromuscular Blocking Agent (NMBA) Report Years Considered
Figure 17. Neuromuscular Blocking Agent (NMBA) Sales Share by Manufacturers in 2024
Figure 18. Global Neuromuscular Blocking Agent (NMBA) Revenue Share by Manufacturers in 2024
Figure 19. The Global 5 and 10 Largest Neuromuscular Blocking Agent (NMBA) Players: Market Share by Revenue in 2024
Figure 20. Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 21. Global Neuromuscular Blocking Agent (NMBA) Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 22. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2018-2034)
Figure 23. North America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2018-2034)
Figure 24. U.S. Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 25. Canada Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 26. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2018-2034)
Figure 27. Europe Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2018-2034)
Figure 28. Germany Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. France Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. U.K. Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Italy Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Russia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2018-2034)
Figure 34. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2018-2034)
Figure 35. China Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. Japan Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. South Korea Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. India Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Australia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. Taiwan Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Indonesia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Thailand Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Malaysia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Philippines Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Latin America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2018-2034)
Figure 46. Latin America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2018-2034)
Figure 47. Mexico Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Brazil Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Argentina Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2018-2034)
Figure 51. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2018-2034)
Figure 52. Turkey Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 53. Saudi Arabia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 54. U.A.E Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Global Sales Market Share of Neuromuscular Blocking Agent (NMBA) by Type (2018-2034)
Figure 56. Global Revenue Market Share of Neuromuscular Blocking Agent (NMBA) by Type (2018-2034)
Figure 57. Global Neuromuscular Blocking Agent (NMBA) Price (USD/MT) by Type (2018-2034)
Figure 58. Global Sales Market Share of Neuromuscular Blocking Agent (NMBA) by Application (2018-2034)
Figure 59. Global Revenue Market Share of Neuromuscular Blocking Agent (NMBA) by Application (2018-2034)
Figure 60. Global Neuromuscular Blocking Agent (NMBA) Price (USD/MT) by Application (2018-2034)
Figure 61. Neuromuscular Blocking Agent (NMBA) Value Chain
Figure 62. Neuromuscular Blocking Agent (NMBA) Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed